Live
FierceBiotechJ&J axes $5B CAR-T dream months after touting best-in-disease efficacyEndpoints NewsSummit slips on ivonescimab's apparent interim miss in sign of investor frustrationEndpoints NewsAmgen files update to Tavneos label as FDA escalates push to withdrawFierceBiotechChutes & Ladders—Astellas appoints new top strategist from Sanofi JapanFierceBiotechLigand tries to disembark from part of Viking pact, alleging contract breachCellBringing the genetically minimal cell to life on a computer in 4DIlluminaCanaccord cuts Illumina stock price target on competition concerns - Investing.comEndpoints NewsSeaport, Hemab price IPOs, while Avalyn soars in Nasdaq debutThermo FisherIs Thermo Fisher’s New U.S. Bioprocess Design Center Shaping a Deeper Biopharma Strategy for TMO? - simplywall.stEndpoints NewsJ&J axes pair of CAR-T therapies for lymphoma, citing evolving marketEndpoints NewsBoehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exitNovo NordiskA proposal seeks to remove Novo and Lilly drugs from key list in the US – will provide better protection against copies - medwatch.com
This story is not available in the archive.